Chinese genome editing startup EdiGene Inc has secured 400 million yuan ($61.7 million) in a Series B+ round of financing led by private equity (PE) firm Loyal Valley Capital to advance its pipeline into clinics and to scale up the business operation.
The Series B+ round roped in new investors BioTrack Capital and Sherpa Healthcare Partners, two China-focused, healthcare venture capital (VC) companies. The firm’s existing investors including IDG Capital, Lilly Asia Venture, 3H Health Investment, Huagai Capital, Sequoia Capital China, Alwin Capital, and Kunlun Capital re-upped in the deal.
